Anti TNF α Improves Endothelial Dysfunction in IBD Patients

UnknownOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2018

Conditions
Crohn's Disease
Interventions
DEVICE

Endopath from Itamar medical - FDA approved device.

endothelial function assessment by Endopath device

DRUG

Anti TNF Alfa.

This study will assessed the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.

Trial Locations (1)

Unknown

RECRUITING

Carmel Medical Center, Haifa

Sponsors
All Listed Sponsors
lead

Carmel Medical Center

OTHER